Added to YB: 2026-04-23
Pitch date: 2026-04-20
HELP [bullish]
Cybin Inc.
+2.85%
current return
Author Info
No bio for this author
Company Info
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
Market Cap
$280.7M
Pitch Price
$5.61
Price Target
9.86 (+71%)
Dividend
N/A
EV/EBITDA
-0.72
P/E
-1.25
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
Helus Pharma ($HELP): A Sleeping Giant in Psychedelic Medicine
HELP: Psychedelic pharma treating depression; Phase 2 showed best results in medical history. $170M cash funds Phase 3 APPROACH trial through Q4 2026 catalyst. Strong composition of matter patents vs peers ($CMPS, $ATAI, $MNMD). Trump EO accelerating FDA psychedelic approvals. Point72 $36M, OrbiMed $31M positions. 100%+ move realistic if Q4 data clean. $300M mcap, high risk.
Read full article (1 min)